Targovax ASA (TRVX):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Targovax ASA (TRVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8239)・商品コード:DATA904C8239
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:44
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥79,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Targovax ASA (Targovax) is a developer and commercializer of immunotherapies for the treatment of cancer patients. The company’s lead candidates include TG0, a peptide-based therapeutic anti-cancer vaccine under development for pancreatic cancer; and ONCOS-102 is an adenovirus-based pipeline product for solid tumor indications. It also provides TG02, TG03, ONCOS-402, ONCOS-802 and ONCOS-902 for other cancer indications. Targovax develops immunotherapies based on treatment approaches harnessing the patient’s immune system to target cancer, which include a virus-based immunotherapy platform based on engineered oncolytic viruses for solid tumors; and a peptide-based immunotherapy platform for RAS-mutated cancers. The company operates through its offices in Norway and Finland. Targovax is headquartered in Oslo, Norway.

Targovax ASA (TRVX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Targovax ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Targovax ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Targovax ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Targovax ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Targovax ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Targovax ASA, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Targovax Raises US$1.3 Million In Venture Financing 11
Targovax Raises US$2.2 Million In Series A Financing 12
Targovax Raises Additional US$1 Million In Venture Financing 13
Partnerships 14
Targovax Enters into Agreement with Sotio 14
Ludwig Institute for Cancer Research and Cancer Research Institute Partner with Targovax 15
Merger 16
Oncos Therapeutics Completes Merger with Targovax 16
Equity Offering 17
Targovax Raises USD0.8 Million in Rights Offering of Shares 17
Targovax Raises USD23.6 Million in Private Placement of Shares 18
Targovax Raises USD0.5 Million in IPO 20
Targovax Raises USD13.3 Million in Private Placement of Shares 21
Targovax Raises USD26 Million in Private Placement of Shares 22
Targovax Raises USD11.6 Million through Shares Issue 24
Targovax ASA – Key Competitors 25
Targovax ASA – Key Employees 26
Targovax ASA – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Feb 15, 2018: Targovax: Fourth quarter and full year 2017 results 28
Apr 25, 2017: Targovax:First quarter 2017 results 30
Feb 16, 2017: Targovax: Fourth quarter and full year 2016 results 31
Corporate Communications 33
Sep 13, 2018: Targovax strengthens management team with the appointment of Torbjorn Furuseth as CFO; Erik Digman Wiklund to become CBO 33
Apr 12, 2018: Targovax strengthens Board of Directors with the appointment of Catherine Wheeler 34
Jan 08, 2018: Targovax announces the appointment of Michael Bogenstaetter as Chief Business Officer 35
Nov 30, 2017: Targovax: New Member of the Board of Directors – Nov. 30, 2017 36
Mar 22, 2017: Targovax: The board of directors of Oslo Stock Exchange approves transfer of Targovax to the main list 37
Jan 05, 2017: Targovax announces appointment of Erik Digman Wiklund as CFO 38
Other Significant Developments 39
Aug 23, 2018: Targovax: Second quarter and first half year 2018 results 39
Jun 11, 2018: Targovax Strengthens Focus on ONCOS Oncolytic Virus Development Program 40
May 03, 2018: Targovax: First quarter 2018 results 41
Nov 02, 2017: Targovax: Third quarter 2017 results 42
Aug 24, 2017: Targovax: Second quarter and first half 2017 results 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Targovax ASA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Targovax ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Targovax ASA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Targovax ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Targovax ASA, Deals By Therapy Area, 2012 to YTD 2018 9
Targovax ASA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Targovax Raises US$1.3 Million In Venture Financing 11
Targovax Raises US$2.2 Million In Series A Financing 12
Targovax Raises Additional US$1 Million In Venture Financing 13
Targovax Enters into Agreement with Sotio 14
Ludwig Institute for Cancer Research and Cancer Research Institute Partner with Targovax 15
Oncos Therapeutics Completes Merger with Targovax 16
Targovax Raises USD0.8 Million in Rights Offering of Shares 17
Targovax Raises USD23.6 Million in Private Placement of Shares 18
Targovax Raises USD0.5 Million in IPO 20
Targovax Raises USD13.3 Million in Private Placement of Shares 21
Targovax Raises USD26 Million in Private Placement of Shares 22
Targovax Raises USD11.6 Million through Shares Issue 24
Targovax ASA, Key Competitors 25
Targovax ASA, Key Employees 26
Targovax ASA, Other Locations 27
Targovax ASA, Subsidiaries 27

List of Figures
Targovax ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Targovax ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Targovax ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Targovax ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Targovax ASA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Targovax ASA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Targovax ASA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Targovax ASA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★調査レポート[Targovax ASA (TRVX):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8239)販売に関する免責事項を必ずご確認ください。
★調査レポート[Targovax ASA (TRVX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆